Aurinia Pharmaceuticals Inc.
AUPH
$15.14
$0.231.54%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 73.47M | 70.01M | 62.47M | 59.87M | 67.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 73.47M | 70.01M | 62.47M | 59.87M | 67.77M |
| Cost of Revenue | 8.50M | 14.55M | 14.32M | 13.66M | 6.34M |
| Gross Profit | 64.96M | 55.46M | 48.15M | 46.21M | 61.43M |
| SG&A Expenses | 26.18M | 26.02M | 20.34M | 37.03M | 42.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 929.00K | 9.25M | 4.43M | 1.39M | 4.57M |
| Total Operating Expenses | 43.72M | 49.81M | 39.09M | 52.09M | 56.02M |
| Operating Income | 29.75M | 20.20M | 23.38M | 7.78M | 11.75M |
| Income Before Tax | 31.96M | 22.16M | 24.35M | 1.17M | 14.81M |
| Income Tax Expenses | 411.00K | 643.00K | 1.01M | -256.00K | 457.00K |
| Earnings from Continuing Operations | 31.55M | 21.51M | 23.34M | 1.43M | 14.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.55M | 21.51M | 23.34M | 1.43M | 14.35M |
| EBIT | 29.75M | 20.20M | 23.38M | 7.78M | 11.75M |
| EBITDA | 34.61M | 25.06M | 28.24M | 12.64M | 16.64M |
| EPS Basic | 0.24 | 0.16 | 0.17 | 0.01 | 0.10 |
| Normalized Basic EPS | 0.15 | 0.10 | 0.12 | 0.07 | 0.06 |
| EPS Diluted | 0.23 | 0.16 | 0.16 | 0.01 | 0.10 |
| Normalized Diluted EPS | 0.15 | 0.10 | 0.11 | 0.07 | 0.06 |
| Average Basic Shares Outstanding | 131.81M | 134.87M | 138.92M | 142.18M | 143.05M |
| Average Diluted Shares Outstanding | 136.01M | 137.53M | 143.20M | 147.68M | 145.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |